{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:47:06Z","timestamp":1786985226451,"version":"build-2736575974"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.biopha.2017.02.042","type":"journal-article","created":{"date-parts":[[2017,3,10]],"date-time":"2017-03-10T23:18:13Z","timestamp":1489187893000},"page":"1061-1066","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Ameliorative effect of chromium-d-phenylalanine complex on indomethacin-induced inflammatory bowel disease in rats"],"prefix":"10.1016","volume":"89","author":[{"given":"S.","family":"Nagarjun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivsharan B.","family":"Dhadde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veeresh P.","family":"Veerapur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.S.","family":"Thippeswamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baburao N.","family":"Chandakavathe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2004","key":"10.1016\/j.biopha.2017.02.042_bib0005","first-page":"394","article-title":"Inflammatory bowel disease: the role of environmental factors","volume":"3","author":"Silvio","year":"2004","journal-title":"Autoim. Rev."},{"key":"10.1016\/j.biopha.2017.02.042_bib0010","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.crohns.2011.01.008","article-title":"Prevalence of irritable bowel syndrome (IBS) in first-degree relatives of patients with inflammatory bowel disease (IBD)","volume":"5","author":"Aguas","year":"2011","journal-title":"J. Crohn's Colitis"},{"key":"10.1016\/j.biopha.2017.02.042_bib0015","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ejphar.2010.12.012","article-title":"Protective effect of embelin against acetic acid induced ulcerative colitis in rats","volume":"654","author":"Thippeswamy","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2017.02.042_bib0020","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1006\/abbi.1995.9932","article-title":"Introduction of nitric oxide synthetase and concomitant supression of SOD in experimental colitis in rats","volume":"324","author":"Seo","year":"1995","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.biopha.2017.02.042_bib0025","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1136\/gut.46.4.487","article-title":"Measurement of in vivo rectal mucosal cytokine and eicosanoid production in ulcerative colitis using filter paper","volume":"46","author":"Carty","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.biopha.2017.02.042_bib0030","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1590-8658(01)80108-0","article-title":"Sulphasalazine and 5-aminosalicylic acid in long-term treatment of ulcerative colitis: report on tolerance and side-effects","volume":"33","author":"Di Paolo","year":"2001","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.biopha.2017.02.042_bib0035","first-page":"S27","article-title":"Cyclosporine nephro toxicity: associated allograft dysfunction at low trough concentration","volume":"56","author":"Jankauskiene","year":"2001","journal-title":"Clin. Nephrol."},{"key":"10.1016\/j.biopha.2017.02.042_bib0040","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ejphar.2004.11.036","article-title":"The effects of selective cyclooxygenase-2 inhibitors celecoxib and rofecoxib, on experimental colitis induced by acetic acid in rats","volume":"507","author":"El-Medany","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2017.02.042_bib0045","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2337\/diaspect.14.3.133","article-title":"Select vitamins and minerals in the management of diabetes","volume":"14","author":"O\u2019Connell","year":"2001","journal-title":"Diabetes Spectr."},{"key":"10.1016\/j.biopha.2017.02.042_bib0050","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.arcmed.2005.01.004","article-title":"Complementary therapies for diabetes: the case for chromium, magnesium, and antioxidants","volume":"36","author":"Guerrero-Romeroa","year":"2005","journal-title":"Arch. Med. Res."},{"key":"10.1016\/j.biopha.2017.02.042_bib0055","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1038\/oby.2007.322","article-title":"Chromium (D-phenylalanine)3 improves obesity-induced cardiac contractile defect in ob\/ob mice","volume":"15","author":"Dong","year":"2007","journal-title":"Obesity"},{"key":"10.1016\/j.biopha.2017.02.042_bib0060","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00394-013-0508-8","article-title":"The effect of chromium on inflammatory markers, 1st and 2nd phase insulin secretion in type 2 diabetes","volume":"53","author":"Yen-Lin","year":"2014","journal-title":"Eur. J. Nutr."},{"key":"10.1016\/j.biopha.2017.02.042_bib0065","first-page":"305","article-title":"Use of D-phenylalanine, and enkephalinase inhibitor, in the treatment of intractable pain","volume":"5","author":"Budd","year":"1983","journal-title":"Adv. Pain Res. Ther."},{"key":"10.1016\/j.biopha.2017.02.042_bib0070","unstructured":"Heller, D-Phenylalanine treatment, US Patent 4355044, 1982."},{"key":"10.1016\/j.biopha.2017.02.042_bib0075","unstructured":"Matsumoto, Therapeutic agent for inflammatory bowel disease and TNF-alfa production inhibitor, US Patent 20080108684 A1, 2008."},{"key":"10.1016\/j.biopha.2017.02.042_bib0080","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jep.2003.09.042","article-title":"Effect of polyherbal formulation on experimental models of inflammatory bowel diseases","volume":"90","author":"Jagtap","year":"2004","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.biopha.2017.02.042_bib0085","first-page":"2370","article-title":"Protein measurement with the phenol reagent","volume":"193","author":"Lowry","year":"1964","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2017.02.042_bib0090","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/0304-4165(90)90100-B","article-title":"Different cellular targets of Cu- and Fe-catalyzed oxidation observed using a Cu-compatible thiobarbiturate acid assay","volume":"1035","author":"Gelvan","year":"1990","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.biopha.2017.02.042_bib0095","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/0003-9861(59)90090-6","article-title":"Tissue sulfhydryl groups","volume":"82","author":"Ellman","year":"1959","journal-title":"Archiv. Biochem. Biophys."},{"key":"10.1016\/j.biopha.2017.02.042_bib0100","first-page":"25","article-title":"Single oral dose toxicity study of \u03b1-cypermethrin in rats","volume":"36","author":"Manna","year":"2004","journal-title":"Indian J. Pharmacol."},{"key":"10.1016\/j.biopha.2017.02.042_bib0105","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1023\/A:1011975218006","article-title":"Novel antioxidants zolimid and AEOL11201 ameliorate colitis in rats","volume":"46","author":"Choudhary","year":"2001","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.biopha.2017.02.042_bib0110","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.jinorgbio.2006.01.039","article-title":"Insulin-sensitizing and cholesterol-lowering effects of chromium (D-Phenylalanine)3","volume":"100","author":"Yang","year":"2006","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.biopha.2017.02.042_bib0115","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/j.febslet.2005.01.049","article-title":"A newly synthetic chromium complex\u2014chromium (phenylalanine)3 improves insulin responsiveness and reduces whole body glucose tolerance","volume":"579","author":"Yang","year":"2005","journal-title":"FEBS. Lett."},{"key":"10.1016\/j.biopha.2017.02.042_bib0120","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/oby.2008.217","article-title":"Chromium alleviates glucose intolerance insulin resistance, and hepatic ER stress in obese mice","volume":"16","author":"Sreejayan","year":"2008","journal-title":"Obesity"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332216328426?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332216328426?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T11:16:47Z","timestamp":1760095007000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332216328426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":24,"alternative-id":["S0753332216328426"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2017.02.042","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ameliorative effect of chromium-d-phenylalanine complex on indomethacin-induced inflammatory bowel disease in rats","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2017.02.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}